CD5 and B-cell chronic lymphocytic leukemia: Compared with mice with TCL1 cells that developed CLL at ∼12 weeks with moderate splenomegaly and a high level of CD19/CD5 double-positive cells in the PB, mice receiving either BM or splenocytes from Asxl1−/−Ezh2−/− CLL mice succumbed to disease in 6 weeks with organomegaly in the spleen, liver, and lymph nodes, and moderate level of circulating CD19/CD5 double-positive cells (Figure 2I; supplemental Figure 2I-K).